Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Lack of Prognostic Significance of C-erbB-2 Expression in Low- and High- grade Astrocytomas

  • Muallaoglu, Sadik (Department of Medical Oncology, Faculty of Medicine, University of Baskent) ;
  • Besen, Ali Ayberk (Department of Medical Oncology, Van Training and Research Hospital) ;
  • Ata, Alper (Department of Medical Oncology, Mersin State Hospital) ;
  • Mertsoylu, Huseyin (Department of Medical Oncology, Faculty of Medicine, University of Baskent) ;
  • Arican, Ali (Department of Medical Oncology, Faculty of Medicine, University of Mersin) ;
  • Kayaselcuk, Fazilet (Department of Pathology, Faculty of Medicine, University of Baskent) ;
  • Ozyilkan, Ozgur (Department of Medical Oncology, Faculty of Medicine, University of Baskent)
  • Published : 2014.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Astrocytic tumors, the most common primary glial tumors of the central nervous system, are classified from low to high grade according to the degree of anaplasia and presence of necrosis. Despite advances in therapeutic management of high grade astrocytic tumors, prognosis remains poor. In the present study, the frequency and prognostic significance of c-erb-B2 in astrocytic tumors was investigated. Materials and Methods: Records of 72 patients with low- and high-grade astrocytic tumors were evaluated. The expression of C-erbB-2 was determined immunohistochemically and intensity was recorded as 0 to 3+. Tumors with weak staining (1+) or no staining (0) were considered Her-2 negative, while tumors with moderate (2+) and strong (3+) staining were considered Her-2 positive. Results: Of the 72 patients, 41 (56.9%) had glioblastoma (GBM), 10 (13.9%) had diffuse astrocytoma, 15 (20.8%) had anaplastic astrocytoma, 6 (8.3%) had pilocytic astrocytoma. C-erbB-2 overexpression was detected in the tumor specimens of 17 patients (23.6%). Six (8.3%) tumors, all GBMs, exhibited strong staining, 2 (2.7%) specimens, both GBMs, exhibited moderate staining, and 9 specimens, 5 of them GBMs (12.5%), exhibited weak staining. No staining was observed in diffuse astrocytoma and pilocytic astrocytoma specimens. Median overall survival of patients with C-erbB-2 negative and C-erbB-2 positive tumors were 30 months (95%CI: 22.5-37.4 months) and 16.9 months (95%CI: 4.3-29.5 months), respectively (p=0.244). Conclusions: Although there was no difference in survival, C-erbB-2 overexpression was observed only in the GBM subtype.

Keywords

References

  1. Albarello L, Pecciarini L, Doglioni C (2011). HER2 testing in gastric cancer. Adv Anat Pathol, 18, 53-9. https://doi.org/10.1097/PAP.0b013e3182026d72
  2. Bauknecht T, Kohler M, Janz I, Pfleiderer A (1989). The occurrence of epidermal growth factor receptors and the characterization of EGF-like factors in human ovarian, endometrial, cervical and breast cancer: EGF receptors and factors in gynecological carcinomas. J Cancer Res Clin Oncol, 115, 193-9. https://doi.org/10.1007/BF00397923
  3. Gehan EA, Walker MD (1997). Prognostic factors for patients with brain tumors. Natl Cancer Inst Monogr, 46,189-95.
  4. Gulati S, Jakola AS, Johannesen TB, Solheim O (2012). Survival and treatment patterns of glioblastoma in the elderly: a population-based study. World Neurosurg, 78, 518-26. https://doi.org/10.1016/j.wneu.2011.12.008
  5. Gulati S, Jakola AS, Nerland US, Weber C, Solheim O (2011). The risk of getting worse: surgically acquired deficits, perioperative complications, and functional outcomes after primary resection of glioblastoma. World Neurosurg, 76, 572-79. https://doi.org/10.1016/j.wneu.2011.06.014
  6. Haapasalo H, Hyytinen E, Sallinen P, et al (1996). c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. Br J Cancer, 73, 620-3. https://doi.org/10.1038/bjc.1996.107
  7. Hiesiger EM, Hayes RL, Pierz DM, Budzilovich GN (1993). Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol, 16, 93-104. https://doi.org/10.1007/BF01324695
  8. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr (2002). HER2/neu expression in malignant lung tumors. Semin Oncol, 29, 51-8.
  9. Haynik DM, Roma AA, Prayson RA (2007). HER-2/neu expression in glioblastoma multiforme. Appl Immunohistochem Mol Morphol, 15, 56-8. https://doi.org/10.1097/01.pai.0000213133.09160.da
  10. Jakola AS, Myrmel KS, Kloster R, et al (2012). Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA, 308, 1881-8. https://doi.org/10.1001/jama.2012.12807
  11. Koka V, Potti A, Forseen SE, et al (2003). Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme. Am J Clin Oncol, 26, 332-5.
  12. Lacroix M, Abi-Said D, Fourney DR, et al (2001). A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg, 95, 190-8. https://doi.org/10.3171/jns.2001.95.2.0190
  13. Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109. https://doi.org/10.1007/s00401-007-0243-4
  14. Mineo JF, Bordron A, Baroncini M, et al (2007). Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol, 85, 281-7. https://doi.org/10.1007/s11060-007-9424-1
  15. Mineo JF, Quintin-Roue I, Lucas B, Buburusan V, Besson G (2002). Glioblastomas: clinical study and search for prognostic factors. Neurochirurgie, 48, 500-9.
  16. Neal DE, Marsh C, Bennett MK, et al (1985). Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet, 1, 366-8.
  17. Ozawa S, Ueda M, Ando N, Shimizu N, Abe O (1989). Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer, 63, 2169-73. https://doi.org/10.1002/1097-0142(19890601)63:11<2169::AID-CNCR2820631117>3.0.CO;2-W
  18. Pfeiffer D, Stellwag B, Pfeiffer A, et al (1989). Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. Gynecol Oncol, 33, 146-50. https://doi.org/10.1016/0090-8258(89)90540-4
  19. Pigott TJ, Robson DK, Palmer J, Ward LM (1993). Expression of epidermal growth factor receptor in human glioblastoma multiforme. Br J Neurosurg, 7, 261-5. https://doi.org/10.3109/02688699309023808
  20. Potti A, Forseen SE, Koka VK, et al (2004). Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors. Cancer Invest, 22, 537-44. https://doi.org/10.1081/CNV-200026523
  21. Rainov NG, Dobberstein KU, Bahn H, et al (2007). Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol, 35, 13-28.
  22. Reszec J, Bernaczyk PS, Milewski R, Chyczewski L, Mariak Z (2011). C-erbB-2 protein expression in astrocytic tumors of the brain. Med Sci Monit, 17, 216-20.
  23. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL (1987). Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet, 1, 1398-402.
  24. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82. https://doi.org/10.1126/science.3798106
  25. Stummer W, Reulen HJ, Meinel T, et al (2008). ALA-Glioma Study Group: Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery, 62, 564-76. https://doi.org/10.1227/01.neu.0000317304.31579.17
  26. Torp SH, Gulati S, Johannessen E, Dalen A (2007). Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study. J Exp Clin Cancer Res, 26, 353-9.
  27. Van den Eynde M, Baurain JF, Mazzeo F, Machiels JP (2011). Epidermal growth factor receptor targeted therapies for solid tumours. Acta Clin Belg, 66, 10-17. https://doi.org/10.1179/ACB.66.1.2062508
  28. Yaziji H, Goldstein LC, Barry TS, et al (2004). HER-2 testing in breast cancer using parallel tissue-based methods. JAMA, 291, 1972-77. https://doi.org/10.1001/jama.291.16.1972

Cited by

  1. Lack of Sunlight Exposure Influence on Primary Glioblastoma Survival vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4165
  2. Preoperative Grading of Astrocytic Supratentorial Brain Tumors with Diffusion-Weighted Magnetic Resonance Imaging and Apparent Diffusion Coefficient vol.13, pp.3, 2016, https://doi.org/10.5812/iranjradiol.30426
  3. Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis vol.140, pp.12, 2017, https://doi.org/10.1002/ijc.30690